Reality Check on Atopic Dermatitis
Market access for atopic dermatitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 26% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In March 2019, the FDA expanded the approval of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in people aged 12 to 17 years whose disease is not adequately controlled with topical prescription therapies or when those treatments are not advisable
- Key Findings: Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after TCSs, TCIs and phototherapy. New market entrants such as these create a new layer of treatment after TCIs and TCSs
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.